Drug
Sitagliptin (JANUVIA®)
Sitagliptin (JANUVIA®) is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
20%(1 trials)
Phase Distribution
Ph phase_4
1
20%
Ph phase_1
1
20%
Ph phase_2
2
40%
Phase Distribution
1
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(5)
Detailed Status
Completed5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (25.0%)
Phase 22 (50.0%)
Phase 41 (25.0%)
Trials by Status
completed5100%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_4
Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis
NCT07439536
completedphase_2
Sitagliptin Plus Granulocyte-colony Stimulating Factor in Acute Myocardial Infarction
NCT00650143
completedphase_1
Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals
NCT00813228
completedphase_2
Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP)
NCT02347501
completed
A Post Marketing Safety Study of Sitagliptin (JANUVIA®) (MK-0431-234)
NCT01354990
Clinical Trials (5)
Showing 5 of 5 trials
NCT07439536Phase 4
Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis
NCT00650143Phase 2
Sitagliptin Plus Granulocyte-colony Stimulating Factor in Acute Myocardial Infarction
NCT00813228Phase 1
Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals
NCT02347501Phase 2
Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP)
NCT01354990
A Post Marketing Safety Study of Sitagliptin (JANUVIA®) (MK-0431-234)
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5